Interpreting results from biomarker-guided clinical trials: avoiding “negative” or “failed” terminology

Nurulamin M. Noor, Haiyan Zheng, David S. Robertson, Joshua Savage, Christina Yap, Andrea L. Jorgensen, James M.S. Wason

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish
Article number314
Number of pages3
JournalBMC medicine
Volume23
Issue number1
Early online date28 May 2025
DOIs
Publication statusPublished - 28 May 2025

Data Availability Statement

No datasets were generated or analysed during the current study.

Acknowledgements

The authors would like to acknowledge the MRC-NIHR Trial Methodology Research Partnership (TMRP) and are all members of the Precision Medicine Working Group.

Funding

N.M.N. is supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312). H.Z. is funded by a Cancer Research UK (CRUK) Research Fellowship (RCCCDF-May24/100001). D.S.R. is funded by the Medical Research Council (MC_UU_00002/14 and MC_UU_00040/03).\u00A0J.S. is funded by CRUK grant C22436/A25354. J.M.S.W. is funded by a NIHR Research Professorship (NIHR301614). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

FundersFunder number
Cancer Research UKRCCCDF-May24/100001
Medical Research CouncilC22436/A25354, MC_UU_00002/14, MC_UU_00040/03
NIHR Cambridge Biomedical Research CentreNIHR203312
National Institute for Health and Care ResearchNIHR301614

Keywords

  • Biomarkers
  • Biomarker-driven
  • Biomarker-guided
  • Biomarker-stratified
  • Precision medicine
  • Clinical trials

Cite this